一名既往未接受过α干扰素治疗的慢性髓性白血病患者在停用伊马替尼后持续获得完全分子学缓解。 - Suppr

Suppr

超能文献

Sustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukemia not previously exposed to interferon alpha.

作者信息

Verma Dushyant, Kantarjian Hagop, Jain Nitin, Cortes Jorge

出版信息

Leuk Lymphoma. 2008 Jul;49(7):1399-402. doi: 10.1080/10428190802043903.

DOI:10.1080/10428190802043903

PMID:18452066

Abstract

摘要

相似文献

Sustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukemia not previously exposed to interferon alpha.

Leuk Lymphoma. 2008 Jul;49(7):1399-402. doi: 10.1080/10428190802043903.

Molecular monitoring in chronic myeloid leukemia patients who achieve complete cytogenetic remission on imatinib.

Blood. 2003 Aug 1;102(3):1143. doi: 10.1182/blood-2002-12-3916.

Sustained cytogenetic response after discontinuation of imatinib mesylate in a patient with chronic myeloid leukaemia.

Eur J Haematol. 2004 Jun;72(6):441-3. doi: 10.1111/j.1600-0609.2004.00257.x.

Sustained complete cytogenetic remission in a patient with chronic myeloid leukemia after discontinuation of imatinib mesylate therapy.

Int J Hematol. 2007 Feb;85(2):173-4. doi: 10.1532/IJH97.06187.

Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience.

Blood. 2002 Jul 15;100(2):435-41. doi: 10.1182/blood.v100.2.435.

Prolonged molecular remission in advanced phase of chronic myeloid leukemia using combination of imatinib and high-dose chemotherapy.

Leuk Lymphoma. 2008 Apr;49(4):815-6. doi: 10.1080/10428190801930514.

Imatinib and pegylated IFN-α2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response.

Eur J Haematol. 2014;92(5):413-20. doi: 10.1111/ejh.12258. Epub 2014 Jan 28.

Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.

Blood. 2003 Jun 15;101(12):4701-7. doi: 10.1182/blood-2002-09-2780. Epub 2003 Feb 6.

Chronic myeloid leukemia presenting with extramedullary disease as massive ascites responding to imatinib mesylate.

Leuk Lymphoma. 2005 Jul;46(7):1097-9. doi: 10.1080/10428190500096781.

Treatment options for chronic myeloid leukemia: imatinib versus interferon versus allogeneic transplant.

Curr Opin Oncol. 2004 Mar;16(2):95-9. doi: 10.1097/00001622-200403000-00002.

引用本文的文献

Minimal Residual Disease Eradication in CML: Does It Really Matter?

Curr Hematol Malig Rep. 2017 Oct;12(5):495-505. doi: 10.1007/s11899-017-0409-7.

Patient preferences for stopping tyrosine kinase inhibitors in chronic myeloid leukemia.

Curr Oncol. 2014 Apr;21(2):e241-9. doi: 10.3747/co.21.1736.

Molecular monitoring.

Curr Hematol Malig Rep. 2014 Mar;9(1):1-8. doi: 10.1007/s11899-013-0192-z.

Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia.

Haematologica. 2012 Jun;97(6):903-6. doi: 10.3324/haematol.2011.056853. Epub 2011 Dec 16.

Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy.

Oncotarget. 2011 Sep;2(9):713-27. doi: 10.18632/oncotarget.333.

NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia.

J Natl Compr Canc Netw. 2011 Feb;9 Suppl 2(0 2):S1-25. doi: 10.6004/jnccn.2011.0125.

Tyrosine kinase inhibitor therapy can cure chronic myeloid leukemia without hitting leukemic stem cells.

Haematologica. 2010 Jun;95(6):900-7. doi: 10.3324/haematol.2009.015271. Epub 2009 Dec 8.

Imatinib and beyond--exploring the full potential of targeted therapy for CML.

Nat Rev Clin Oncol. 2009 Sep;6(9):535-43. doi: 10.1038/nrclinonc.2009.112. Epub 2009 Aug 4.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验